Neogen (NEOG) Return on Capital Employed (2011 - 2026)
Neogen's (NEOG) quarterly Return on Capital Employed came in at 19.82% in Q1 2026, up 41258.0% year-on-year from N/an in Q1 2025, and down 1.8% quarter-over-quarter from 19.47% in Q4 2025.
Neogen (NEOG) Return on Capital Employed (2011 - 2026) Analysis & Trends
Neogen's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 19.82% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 41258.0% year-over-year to 19.82% in Q1 2026; TTM through Feb 2026 was 19.82%, a 41258.0% increase from a year earlier, with the FY2025 full-year figure at 27.76%, down 2909.0% from the prior year.
- Return on Capital Employed eased to 19.82% in Q1 2026 per NEOG's latest filing, from 19.47% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 6.69% in Q1 2022 and bottomed at 432.4% in Q1 2025.
- The 5-year median for Return on Capital Employed is 0.87% (2022), against an average of 33.03%.
- Across the five-year window, Return on Capital Employed tumbled 43395 bps in 2025 and surged 41258 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 0.87% in 2022, then soared by 89 bps to 1.65% in 2023, then tumbled by 1438 bps to 22.09% in 2024, then grew by 12 bps to 19.47% in 2025, then decreased by 2 bps to 19.82% in 2026.
- Per Business Quant, the three latest NEOG Return on Capital Employed figures stand at 19.82% (Q1 2026), 19.47% (Q4 2025), and 33.06% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Neogen | 2.09 Bn | 1.93 Bn | 99.00 Mn | -19.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -19.82% |
| Nov 30, 2025 | -19.47% |
| Aug 31, 2025 | -33.06% |
| May 31, 2025 | -61.69% |
| Feb 28, 2025 | -432.40% |
| Nov 30, 2024 | -22.09% |
| Aug 31, 2024 | 1.00% |
| May 31, 2024 | 1.33% |
| Feb 29, 2024 | 1.56% |
| Nov 30, 2023 | 1.65% |
| Aug 31, 2023 | 1.14% |
| May 31, 2023 | 0.86% |
| Feb 28, 2023 | 0.73% |
| Nov 30, 2022 | 0.87% |
| Aug 31, 2022 | 4.68% |
| May 31, 2022 | 6.45% |
| Feb 28, 2022 | 6.69% |
| Nov 30, 2021 | 7.92% |
| Aug 31, 2021 | 8.80% |
| May 31, 2021 | 6.30% |